1. Home
  2. HZO vs CINGW Comparison

HZO vs CINGW Comparison

Compare HZO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HZO
  • CINGW
  • Stock Information
  • Founded
  • HZO 1998
  • CINGW N/A
  • Country
  • HZO United States
  • CINGW United States
  • Employees
  • HZO N/A
  • CINGW 13
  • Industry
  • HZO Auto & Home Supply Stores
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • HZO Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • HZO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • HZO N/A
  • CINGW N/A
  • IPO Year
  • HZO 1998
  • CINGW 2021
  • Fundamental
  • Price
  • HZO $21.98
  • CINGW $0.06
  • Analyst Decision
  • HZO Strong Buy
  • CINGW
  • Analyst Count
  • HZO 6
  • CINGW 0
  • Target Price
  • HZO $41.50
  • CINGW N/A
  • AVG Volume (30 Days)
  • HZO 324.0K
  • CINGW N/A
  • Earning Date
  • HZO 04-24-2025
  • CINGW N/A
  • Dividend Yield
  • HZO N/A
  • CINGW N/A
  • EPS Growth
  • HZO N/A
  • CINGW N/A
  • EPS
  • HZO 2.38
  • CINGW N/A
  • Revenue
  • HZO $2,372,195,000.00
  • CINGW N/A
  • Revenue This Year
  • HZO $0.66
  • CINGW N/A
  • Revenue Next Year
  • HZO $5.76
  • CINGW N/A
  • P/E Ratio
  • HZO $9.22
  • CINGW N/A
  • Revenue Growth
  • HZO N/A
  • CINGW N/A
  • 52 Week Low
  • HZO $21.00
  • CINGW N/A
  • 52 Week High
  • HZO $38.20
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • HZO 34.93
  • CINGW N/A
  • Support Level
  • HZO $21.00
  • CINGW N/A
  • Resistance Level
  • HZO $23.83
  • CINGW N/A
  • Average True Range (ATR)
  • HZO 0.93
  • CINGW 0.00
  • MACD
  • HZO 0.02
  • CINGW 0.00
  • Stochastic Oscillator
  • HZO 31.72
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: